在一项暴露前预防随机安慰剂对照试验（ANRS-IPERGAY）中血清转化者早期治疗期间的炎症标志物
Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY).
作者信息
Chawki Sylvain, Charreau Isabelle, Gabassi Audrey, Carette Diane, Cua Eric, Cotte Laurent, Pialoux Gilles, Pintado Claire, Meyer Laurence, Chaix Marie-Laure, Delaugerre Constance, Molina Jean-Michel
机构信息
Department of Virology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
INSERM U944, Paris University, Paris, France.
出版信息
Open Forum Infect Dis. 2021 Mar 20;8(3):ofab085. doi: 10.1093/ofid/ofab085. eCollection 2021 Mar.
HIV-related inflammation is associated with poor outcomes. We describe inflammatory biomarkers in 17 participants in a pre-exposure prophylaxis trial who seroconverted with very early initiation of antiretroviral therapy. Inflammation peaked at the time of HIV infection and returned to baseline within 6-12 months. Starting antiretroviral therapy very early could help mitigate long-lasting HIV-related inflammation.
与HIV相关的炎症与不良预后相关。我们描述了17名参与暴露前预防试验的参与者的炎症生物标志物，这些参与者在极早期开始抗逆转录病毒治疗后发生了血清转化。炎症在HIV感染时达到峰值，并在6至12个月内恢复到基线水平。极早期开始抗逆转录病毒治疗可能有助于减轻长期的HIV相关炎症。
Zotero 插件